Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

unknown1
Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown133%
not_yet_recruiting133%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationphase_2

Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis

NCT06999148
not_yet_recruitingphase_3

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

NCT06477939
unknownphase_2

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

NCT04244708

Clinical Trials (3)

Showing 3 of 3 trials
NCT06999148Phase 2

Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis

Enrolling By Invitation
NCT06477939Phase 3

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Not Yet Recruiting
NCT04244708Phase 2

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3